You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 1 - 25 of 169
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Oct 14, 2022

Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • Tislelizumab
  • Tislelizumab, Lenvatinib
  • (no location specified)
Mar 29, 2023

Immunotherapy Trial (Tislelizumab, Capecitabine, oxaliplatin)

Not yet recruiting
  • Immunotherapy
  • Tislelizumab
  • +4 more
  • (no location specified)
Jul 28, 2022

Recurrent Hepatocellular Carcinoma Trial in Guangzhou (Tislelizumab, Tislelizumab combined with Levatinib)

Recruiting
  • Recurrent Hepatocellular Carcinoma
  • Tislelizumab
  • Tislelizumab combined with Levatinib
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Mar 31, 2022

Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)

Not yet recruiting
  • Esophageal Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Nov 18, 2022

Gastric Cancer Trial (Tislelizumab, 5Fu, Paclitaxel injection)

Not yet recruiting
  • Gastric Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Feb 21, 2023

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • +3 more
  • Tislelizumab
  • (no location specified)
Apr 23, 2023

Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • (no location specified)
Apr 11, 2023

Non Small Cell Lung Cancer Trial (Tislelizumab, Ociperlimab, LBL-007)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Tislelizumab
  • +2 more
  • (no location specified)
Jan 30, 2023

Pancreatic Tumors Trial (Tislelizumab)

Not yet recruiting
  • Pancreatic Neoplasms
  • Tislelizumab
  • (no location specified)
Dec 26, 2022

Melanoma Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Melanoma
  • Tislelizumab
  • +2 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 8, 2022

Gastric Cancer Stage IV Trial (Oxaliplatin, Levo-Leucovorin, 5-fluorouracil)

Not yet recruiting
  • Gastric Cancer Stage IV
  • (no location specified)
Nov 13, 2022

Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Tislelizumab
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Institute & Hospital
May 24, 2022

Nasopharyngeal Carcinoma Trial in Beijing (Tislelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Tislelizumab
  • Beijing, Beijing, China
    National Cancer Center /National Clinical Research Center for Ca
Jul 4, 2022

NSCLC Trial in Zhengzhou (Tislelizumab)

Active, not recruiting
  • NSCLC
  • Tislelizumab
  • Zhengzhou, Hennan, China
    The First Affiliated Hospital of Zhengzhou University
Oct 31, 2022

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)

Recruiting
  • Stage III Non-small Cell Lung Cancer
  • Neoadjuvant chemo-immunotherapy
  • +5 more
  • Guangzhou, China
    Sun Yat-sen University
Jul 19, 2022

Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)

Not yet recruiting
  • Biliary Tract Carcinoma
  • Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Apr 10, 2023

Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Mar 23, 2023

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Pancreatic Cancer Trial in Baltimore (Tislelizumab, SX-682)

Not yet recruiting
  • Pancreatic Cancer
  • Baltimore, Maryland
    Johns Hopkins SKCCC
Jan 23, 2023

Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)

Not yet recruiting
  • Immunotherapy Esophagus Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)

Active, not recruiting
  • Muscle Invasive Bladder Cancer
  • Urothelial Carcinoma
  • Tislelizumab
  • Nab paclitaxel
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Nov 23, 2022

Head Neck Cancer Trial in Chengdu, Tianjin (Tislelizumab, Pulse radiation)

Recruiting
  • Head and Neck Cancer
  • Tislelizumab
  • Pulse radiation
  • Chengdu, Sichuan, China
  • +1 more
Oct 25, 2022

Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Tislelizumab
  • +4 more
  • Wuhan, Hubei, China
  • +2 more
Jan 16, 2023